Valuation: Genmab A/S

Capitalization 11TCr 1.65TCr 1.41TCr 1.29TCr 1.22TCr 2.26TCr 1,57900Cr 2.29TCr 15TCr 5.99TCr 75TCr 6.19TCr 6.06TCr 2,60200Cr P/E ratio 2026 *
23.3x
P/E ratio 2027 * 15.8x
Enterprise value 12TCr 1.95TCr 1.67TCr 1.53TCr 1.45TCr 2.68TCr 1,87100Cr 2.71TCr 18TCr 7.09TCr 89TCr 7.34TCr 7.18TCr 3,08400Cr EV / Sales 2026 *
4.54x
EV / Sales 2027 * 3.53x
Free-Float
95.8%
Yield 2026 *
-
Yield 2027 * -
1 day+3.22%
1 week-1.35%
Current month+1.33%
1 month-4.33%
3 months-8.96%
6 months-12.87%
Current year-15.52%
1 week 1,546
Extreme 1546
1,795
1 month 1,546
Extreme 1546
1,873.5
Current year 1,546
Extreme 1546
2,257
1 year 1,268.5
Extreme 1268.5
2,257
3 years 1,157
Extreme 1157
2,939
5 years 1,157
Extreme 1157
3,327
10 years 786.2
Extreme 786.2
3,327
Manager TitleAgeSince
Chief Executive Officer 65 01/06/2010
Director of Finance/CFO 48 01/03/2020
Chief Tech/Sci/R&D Officer - 16/08/2024
Director TitleAgeSince
Chairman 65 26/03/2020
Director/Board Member 75 01/11/2003
Director/Board Member 66 01/01/2017
Change 5d. change 1-year change 3-years change Capi.($)
+3.22%-1.35%+29.73%-40.31% 1.61TCr
+1.01%+2.89%+40.00%+88.60% 5.07TCr
+1.48%+0.71%+86.81%+62.75% 4.86TCr
+0.34%-1.93%-3.71%-11.00% 2.36TCr
+11.66%-16.81%+71.22%+519.33% 2.25TCr
+1.94%-0.41%+44.95%-26.82% 1.75TCr
-0.99%+1.72%+63.52%+205.52% 1.54TCr
+1.55%+8.04%-24.98%+1,001.74% 1.45TCr
+2.58%+0.88%+50.20% - 1.34TCr
-0.50%+11.35%+33.75%+157.87% 1.25TCr
Average +2.23%-0.64%+39.15%+217.52% 2.35TCr
Weighted average by Cap. +2.19%-0.73%+45.74%+169.50%

Financials

2026 *2027 *
Net sales 2.75TCr 430.98Cr 367.58Cr 337.12Cr 319.11Cr 591.39Cr 41TCr 597.03Cr 4.02TCr 1.56TCr 20TCr 1.62TCr 1.58TCr 68TCr 3.24TCr 507.67Cr 432.99Cr 397.11Cr 375.89Cr 696.62Cr 49TCr 703.27Cr 4.73TCr 1.84TCr 23TCr 1.9TCr 1.86TCr 80TCr
Net income 460.73Cr 72Cr 62Cr 57Cr 54Cr 99Cr 6.92TCr 100.16Cr 673.57Cr 262.3Cr 3.28TCr 271.3Cr 265.58Cr 11TCr 702.63Cr 110.26Cr 94Cr 86Cr 82Cr 151.3Cr 11TCr 152.74Cr 1.03TCr 400.02Cr 5.01TCr 413.74Cr 405.01Cr 17TCr
Net Debt 1.94TCr 305.17Cr 260.28Cr 238.71Cr 225.95Cr 418.75Cr 29TCr 422.75Cr 2.84TCr 1.11TCr 14TCr 1.15TCr 1.12TCr 48TCr 905.27Cr 142.06Cr 121.16Cr 111.12Cr 105.18Cr 194.93Cr 14TCr 196.79Cr 1.32TCr 515.39Cr 6.45TCr 533.06Cr 521.82Cr 22TCr
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,088
Date Price Change Volume
12/26/12 1,712.50 kr +3.22% 1,76,191
11/26/11 1,659.00 kr +1.07% 2,07,047
08/26/08 1,641.50 kr -6.65% 6,42,235
07/26/07 1,758.50 kr -0.62% 1,37,633
06/26/06 1,769.50 kr +1.93% 1,14,887
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
1,712.50DKK
Average target price
2,316.19DKK
Spread / Average Target
+35.25%

Quarterly revenue - Rate of surprise